Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular.
Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally combine biology and chemistry expertise and offer integrated drug discovery services to clients.
“This new deal will result in an increase in our technological capabilities, expansion of facilities, new opportunities for Aurelia scientists and a growth in our resource base. Being a part of a larger group will help Aurelia Bioscience serve our clients better, whilst maintaining a personal touch that the company strives to provide in every project.”, said Dr. Gary Allenby, CEO and Co-founder at Aurelia Bioscience.
Image credit: Cytonn Photography
